A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00569621
• Date of registration: 05/12/2007
• Primary sponsor: Medical University of Vienna
• Public title: A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow
• Scientific title: A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow
• Date of first enrolment: March 2007
• Target sample size: 16
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00569621
• Study type: Interventional
• Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Countries of recruitment

Austria

Contacts

• Name: Michael Wolzt, Prof
• Affiliation: Department of Clinical Pharmacology

Key inclusion & exclusion criteria

Inclusion Criteria:

- 6 healthy volunteers of either sex

- Age 18-35 yrs.

- Body mass index between 15th and 85th percentile, nonsmokers

Exclusion Criteria:

- Regular use of medication

- Abuse of alcoholic beverages or drugs

- Participation in a clinical trial in the 3 weeks preceding the study

- Treatment in the previous 3 weeks with any drug

- Symptoms of a clinically relevant illness in the 3 weeks before the first study day

- History or presence of gastrointestinal, liver or kidney disease, or other conditions
known to interfere with distribution, metabolism or excretion of study drugs

- Blood donation during the previous 3 weeks

- Ametropy less 3 dpt

- Acute gastric bleeding, massive cerebral hemorrhage related to stroke

- Women: pregnancy or lactation.



Age minimum: 18 Years
Age maximum: 35 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Ischemia

Intervention(s)

Drug: Moxaverine

Drug: physiological saline

Primary Outcome(s)

Retinal and Choroidal Blood flow [Time Frame: 2 hours]

Secondary ID(s)

MOXOPH1

Source(s) of Monetary Support

Please refer to primary and secondary sponsors